Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
190 questions in 24 reviews · Epilepsy
current versionsNo studies 190 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Immunomodulatory interventions vs placebo Seizure freedom · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Allergic reactions · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Cognitive effects · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Immunomodulatory interventions vs placebo Quality of life · people with focal epilepsy Immunomodulatory interventions for focal epilepsy (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Primary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary seizure prophylaxis after stroke · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary outcomes · patients with stroke Antiepileptic drugs for the primary and secondary prevention of seizures after stroke (2022) · Cochrane | no estimate extracted | NR | No studies |
Add‐on stiripentol vs add‐on placebo Quality of life · people with drug‐resistant focal epilepsy Stiripentol add‐on therapy for drug‐resistant focal epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with focal seizures Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with focal seizures Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Comparison (reference treatment) · adults and children with generalised seizures* Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants seizure‐free at 12 months after randomization ‐ not reported · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants with TEAEs leading to discontinuation during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants seizure‐free at 24 months after randomization ‐ not reported · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs carbamazepine Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants seizure‐free at 12 months after randomization · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants seizure‐free at 24 months after randomization · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of responders (those with at least a 50% reduction in seizure frequency from baseline to end of treatment) · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Clonazepam vs ethosuximide Proportion of participants with treatment‐emergent adverse events (TEAEs) during the treatment period · people with newly diagnosed epilepsy Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only ADHD symptoms · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Osmotic‐release oral system methylphenidate vs placebo Proportion of people experiencing 50% or greater reduction in seizure frequency · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only Seizure severity · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral levetiracetam vs placebo (any antipyretics) Recurrent seizures at 18 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral levetiracetam vs placebo (any antipyretics) Recurrent seizures at 24 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral levetiracetam vs placebo (any antipyretics) Recurrent seizures at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral levetiracetam vs placebo (any antipyretics) Recurrent seizures at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral levetiracetam vs placebo (any antipyretics) Recurrent seizures at 60 months or greater · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous phenobarbital vs placebo or no treatment Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous phenobarbital vs placebo or no treatment Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent phenobarbital vs placebo or no treatment Recurrent seizure at 18 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent phenobarbital vs placebo or no treatment Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent phenobarbital vs placebo or no treatment Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 6 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 18 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 24 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral phenytoin vs placebo Recurrent seizure at 60 months or greater · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral valproate vs placebo or no treatment Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral valproate vs placebo or no treatment Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral valproate vs placebo or no treatment Recurrent seizure at 60 months or greater · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral pyridoxine vs placebo Recurrent seizure at 18 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral pyridoxine vs placebo Recurrent seizure at 24 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral pyridoxine vs placebo Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral pyridoxine vs placebo Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Continuous oral pyridoxine vs placebo Recurrent seizure at 60 months or greater · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral ibuprofen vs placebo Recurrent seizure at 18 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral ibuprofen vs placebo Recurrent seizure at 36 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |
Intermittent oral ibuprofen vs placebo Recurrent seizure at 48 months · children with febrile seizures Prophylactic drug management for febrile seizures in children (2021) · Cochrane | no estimate extracted | NR | No studies |